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Nuclear factor κB (NF-κB) is a transcription factor that regulates
various aspects of immune response, cell death, and differentiation
as well as cancer. In this study we introduce the Py-Im polyamide 1
that binds preferentially to the sequences 5′-WGGWWW-3′ and 5′
GGGWWW-3′. The compound is capable of binding to κB sites and
reducing the expression of various NF-κB–driven genes including
IL6 and IL8 by qRT-PCR. Chromatin immunoprecipitation experi-
ments demonstrate a reduction of p65 occupancy within the prox-
imal promoters of those genes. Genome-wide expression analysis
by RNA-seq compares the DNA-binding polyamide with the well-
characterized NF-κB inhibitor PS1145, identifies overlaps and differ-
ences in affected gene groups, and shows that both affect compar-
able numbers of TNF-α–inducible genes. Inhibition of NF-κB DNA
binding via direct displacement of the transcription factor is a
potential alternative to the existing antagonists.
gene regulation ∣ small molecule ∣ plasminogen activator inhibitor 1
NF-κB encompasses a family of transcription factors that playa pivotal role in the inflammatory response, cell prolifera-
tion, and survival (1). It has been broadly implicated in cancer
(2) and is a major contributor towards cellular senescence (3).
The regulatory network of NF-κB has been studied at a high level
of detail since its original discovery (4). Briefly, in the absence
of stimulus such as tumor necrosis factor α (TNF-α), lipopolysac-
charide, or interleukin 1 (IL1), NF-κB is sequestered in the
cytosol in its inactive form, complexed to the inhibitory proteins
of the IκB family. An induction signal leads to the activation of
the IκB kinase complex (IKK), which targets the inhibitor pro-
teins for ubiquitylation and proteasome-mediated degradation.
The unmasked NF-κB proteins subsequently translocate into the
cell nucleus, bind their target DNA sequences, termed κB sites
(GGGRNYYYCC, where R ¼ purine, Y ¼ pyrimidine, and N ¼
any base) and activate various gene programs, depending on the
stimulus nature (5). The central biological importance of this tran-
scription factor family together with its detailed structural and
functional understandingmakes it a particularly attractive drug tar-
get. A plethora of NF-κB inhibitors has been developed, which tar-
get different portions of the regulatory circuit (6). NF-κB regulates
a vast number of cell processes, and its knockdown can have detri-
mental effects. It would therefore be useful to develop a strategy
with which the expression of gene subgroups could be modulated
while leaving the transcription factor itself intact.
Our laboratory has developed pyrrole-imidazole (Py-Im) poly-
amides as a class of modular DNA minor groove binders with
affinities and specificities comparable to those of DNA-binding
proteins (7–10). The minor groove binding of the DNA leads to
the compression of the major groove that antagonizes transcrip-
tion factor binding to the DNA major groove in an allosteric
fashion (11). To date, they have been successfully applied in cell
culture experiments to modulate the activity of the hypoxia indu-
cible factor 1α, the androgen receptor, and the glucocorticoid
receptor by our laboratory (12–15). Displacement of NF-kB
by polyamides was also shown by electrophoretic mobility shift
assays (16, 17). Matsuda and co-workers independently demon-
strated that a Py-Im polyamide could be used to target the TGF-β
promoter (18). Small molecule inhibitors mostly act upstream
of the NF-κB DNA-binding event. They typically interfere with
either the release of the transcription factor from the IκB com-
plex or the DNA-binding ability of NF-κB, which can lead to
broad and undesired side effects. The use of polyamide-based
drugs to selectively disrupt the NF-κB binding to a subset of κB
sites without compromising the overall functionality of the tran-
scription factor could represent an interesting alternative to the
existing small molecule inhibitors.
Results
NF-κB ChIP-seq.ChIP-seq experiments with a p65-specific antibody
were conducted to gain better understanding of NF-κB binding in
cell culture (A549, human non-small lung carcinoma). The high-
est occupancy of the proximal promoters of the known NF-κB
target genes IL6 and IL8 was observed after 30 min TNF-α in-
duction (Fig. S1). This time point was therefore chosen for
ChIP-seq experiments. The predominant binding motif was deter-
mined as NGGNNTTTCCN by an unbiased search (Fig. 1A), in
good agreement with the recent study conducted for a panel of
lymphoblastoid cell lines (19).
The determined sequence was employed to guide polyamide
design, yielding the Py-Im polyamide 1 ½ImImPyPy-ðRÞα-aminoγ-
PyPyPyPy, specific for the DNA sequence 5′WGGWWW-3′
according to the pairing rules (10).
Py-Im Polyamide 1 Binds to the κB Sites within the IL6 and IL8 Promo-
ter. Following the guidelines from the ChIP-seq experiment, the
polyamide 1 capable of binding the sequence 5′-WGGWWW-3′
was synthesized (Fig. 1B). An initial set of DNA melting tem-
perature analyses was conducted to assess the binding propensity
of 1 towards the matched binding site (5′-WGGWWW-3′) as well
as that bearing a single mismatch over the polyamide C terminus
(5′GGGWWW-3′). These two sequences are found in a large
number of κB sites and hence possess a biological significance.
For our initial experiments, the genes IL6 and IL8 were chosen.
Their NF-κB response elements (κB sites) possess the sequence
5′-GGGATTTTCCC-3′ (chr7:22,766,746-22,766,756) and 5′
GTGGAATTTCC-3′ (chr4:74,606,193-74,606,203), on the Uni-
versity of California Santa Cruz 2009 human genome browser
(hg19), respectively (20, 21). In either of the κB sites, 1 is capable
of binding in two orientations (Fig. 1C), which corresponds to
the portions of the κB sites recognized by the p50 and the p65
subunit, respectively (1–5).
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The DNA melting temperature was raised by 12.3ð0.6Þ °C
(IL6 κB site) and 10.7ð0.2Þ °C (IL8 κB site) upon addition of 1,
thus indicating its significant binding to the two DNA sequences
(Table 1, entries 1 and 4). Further oligonucleotides were designed
to probe the binding of 1 to the fragments of the κB sites repre-
senting the p50 and p65 recognition elements (Table 1, entries 2–
3 for IL6 and 5–6 for IL8). The melting temperatures of the DNA
duplexes experienced similar magnitudes of temperature increase
upon polyamide addition. Quantitative DNase I footprint titra-
tion experiments of this Py-Im polyamide core have been pre-
viously reported by our laboratory (Ka ¼ 5 × 108 M−1) (8).
Cellular Uptake of 1. The fluorescent FITC conjugate of 1 (3) was
synthesized and its nuclear uptake studied in the A549 cell line
(lung carcinoma). Robust reproducible cellular uptake was ob-
served by confocal microscopy after 12–16 h incubation. Further
evidence for cellular uptake of unmodified 1 was obtained by
measuring compound cytotoxicity in live cells at different incuba-
tion time points (Fig. S2).
Inhibition of NF-κB Regulated IL6 and IL8 Expression. Encouraged by
the favorable DNA-binding and cellular uptake properties of 1,
mRNA expression levels of IL6 and IL8 in response to polyamide
treatment were investigated by qRT-PCR. Incubation of cells with
1 at a 10 μM concentration for 48 h, followed by a TNF-α stimu-
lation for 12 h resulted in a significant reduction of both the IL6
and IL8 expression (Fig. 2A, 2.3-fold in both cases). The effects
were more pronounced after 72 h incubation, the mRNA down-
regulation being 6.5-fold and 4-fold for IL6 and IL8, respectively.
Consistent transcript repression of both IL6 and IL8 was also
seen at an earlier TNF-α induction time point (Fig. S3A). The
expression levels of the housekeeping genes used [peptidylproly-
lisomerase A (PPIA) and glucuronidase, beta (GUSB)] remained
stable upon treatment with 1. The mRNA reduction correlated
well with the protein levels as assessed by ELISA (Fig. S3B). In
a control experiment we tested the effects of a κB-site mismatch
polyamide by flipping the internal Im-Py pair of 1, which would
result in targeting of the 5′-WGCWWW-3′ sequence according to
our DNA recognition rules. The relevant Tm analyses are sum-
marized in Table S1. The effects of the resulting oligomer
ImPyPyPy-ðRÞα-aminoγ-PyPyImPy (10) on the expression of IL6
and IL8 were substantially lower as compared to 1. A represen-
tative experiment is shown in Fig. S4 A and B. The ability of the
scrambled polyamide to traffic to the nucleus of A549 was as-
sessed by studying the uptake of its FITC-conjugate analog 11
(Fig. S4 C and D).
The ability of 1 to disrupt NF-κB binding to the characterized
κB sites within the IL6 and IL8 promoters was examined by con-
ducting ChIP-qPCR experiments on the corresponding genomic
loci. The IL6 promoter occupancy was reduced twofold upon
polyamide treatment, whereas with IL8 the effect was less pro-
nounced with 1.5-fold reduction of promoter occupancy (Fig. 2B).
Western blot analyses were conducted to assess the nuclear levels
of p65 in response to the treatment with the Py-Im polyamide
1. The compound was found not to affect the p65 trafficking
to the nucleus in both uninduced (Fig. 2C) and TNF-α–induced
(Fig. 2D) A549 cells. The use of the kinase inhibitor PS1145 led
to the expected partial attenuation of TNF-α–induced p65 trans-
location in a control experiment (22).
Similarly to TNF-α, IL1 can be used to activate the canonical
NF-κB gene expression program (23). IL1 signals through the cell
surface receptor IL1R, employing a different signaling cascade
upstream of NF-κB activation than TNF-α, which signals through
the tumor necrosis factor receptor. However, both the IL1 and
the TNF-α stimulation ultimately result in the ubiquitylation of
IκB inhibitory proteins, the translocation of the p50:p65 dimer
into the nucleus, and the activation of canonical gene transcrip-
tion. The Py-Im polyamide 1 being a DNA-binding molecule,
one would anticipate that the difference in signaling upstream
of NF-κB activation and nuclear translocation should not affect
the effects of 1 on the expression of NF-κB–dependent genes. To
this end, we assayed for the difference in expression of IL6 and
IL8 upon treatment with the polyamide in a set of experiments
where IL1 was used as the inducing agent (Fig. 3). Paralleling
the observations made in the TNF-α–induction experiments
(Fig. 2A and Fig. S3A), we measured decreased levels of both
IL6 and IL8 transcripts by qRT-PCR. Again, an incubation with
1 for 72 h prior to the IL1 stimulation led to a more substantial
repression of IL6 (2.3-fold at 10 μM) and IL8 (1.9-fold at 10 μM)
than an incubation for 48 h (1.6-fold and 1.5-fold, respectively).
Genome-wide Polyamide Effects on TNF-α–Induced Gene Expression.
Given the ability of 1 to down-regulate the mRNA expression of
IL6 and IL8, a series of RNA-seq experiments was conducted
to establish the global effects of 1 on the TNF-α–inducible A549
transcriptome. The kinase inhibitor PS1145 (2) (Fig. 1B) was
used as the reference molecule with a well-defined mechanism of
action. A total of 979 genes (2.0% of the interrogated transcrip-
Fig. 1. (A) The NF-κB binding site determined by ChIP-seq. (B) The polyamide
1 and the IκB kinase inhibitor PS1145 2. (C) The targeted NF-κB response ele-
ments within the IL6 and IL8 promoter with the likely polyamide binding
modes.
Table 1. Sequences used in the Tm analyses of 1
Entry κB site Sequence Tm DNA ΔTm
1 IL6 5′-TGGGATTTTCCCAT-3′ 55.1 (±0.3) 12.3 (±0.6)
2 IL6P50 5′-TGTGGGATTTT-3′ 47.3 (±0.1) 12.1 (±0.3)
3 IL6P65 5′-ATTTTCCCATG-3′ 44.0 (±0.3) 13.2 (±0.9)
4 IL8 5′-CGTGGAATTTCCTC-3′ 56.4 (±0.1) 10.7 (±0.2)
5 IL8P50 5′-TCGTGGAATTT-3′ 46.2 (±0.5) 13.3 (±0.8)
6 IL8P65 5′-GAATTTCCTCT-3′ 43.7 (±0.6) 14.9 (±0.6)
Tm and ΔTm values are reported in °C.
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tome) had an expression change of more than twofold upon TNF-α
stimulation.Within this subpopulation, 650 genes were up- and 329
down-regulated (Fig. 4 A and B). The polyamide 1 affected 1196
(2.4%) genes from which 671 were down-regulated with respect to
the TNF-α stimulated reference. The kinase inhibitor 2 affected an
approximately twofold smaller group of genes than the polyamide
(613 genes, 1.2%, from which 332 were repressed).
From the 650 genes that were induced by TNF-α, only 67 were
repressed by both 1 and 2 (Fig. 3A). In addition to those, 115
genes were found overlapping between TNF-α (up) and 1 (down)
that were unaffected by 2. Complementing that, there was an
overlapping subgroup of 99 genes between TNF-α (up) and 2
(down) that was not affected by 1. A large fraction of genes was
found in nonoverlapping regions between the gene pools affected
by TNF-α, 1 or 2. From the 650 genes that were induced by
Fig. 2. (A) Changes in mRNA expression levels of IL6 and IL8 normalized to PPIA (48 or 72 h incubation with 1 at 5 or 10 μM, followed by an induction with
TNF-α for 12 h, where indicated). (B) Genomic occupancy at the IL6 and IL8 proximal promoter (72 h incubation with 1 at 10 μM followed by an induction with
TNF-α for 30 min). See Fig. S5 for further time course details. (C–D) Western blot analyses to assess cytoplasmic and nuclear p65 levels in response to the
treatment with the Py-Im polyamide 1. A549 cells were incubated with 1 for 72 h and induced with TNF-α for 6 h, where indicated. Treatment with 2 was
commenced 1.5 h prior to TNF-α induction. (C) Treatment with 1 does not alter basal nuclear p65 level. Nuclear (Left) and cytoplasmic (Right) extracts were
analyzed for p65 protein levels. Purity of the nuclear and cytoplasmic extracts and normalization of loading were confirmed by probing for the nuclear protein
lamin A/C and the cytoplasmic protein α-tubulin. (D) Treatment with 1 does not inhibit TNF-induced p65 nuclear translocation. Nuclear (Left) and cytoplasmic
(Right) extracts were analyzed for p65 protein levels. 2 was used as a control for inhibition of TNF-α–induced p65 nuclear translocation. Purity of the nuclear
and cytoplasmic extracts and normalization of loading were confirmed by probing for the nuclear protein lamin A/C and the cytoplasmic protein α-tubulin.
Fig. 3. Changes in mRNA expression levels of IL6 and IL8 normalized to PPIA
(48 or 72 h incubation with 1 at 5 or 10 μM, followed by an induction with IL1
for 2 h, where indicated).
Fig. 4. RNA-seq global transcriptome analysis; all ratios are normalized to
the induced state. (A) Venn diagrams for the overlap between TNF-α–induced
genes and those repressed by 1 or 2 (all at least twofold). (B) Venn diagrams
for the overlap between TNF-α–repressed genes and those induced by 1 or 2
(all at least twofold). (C) Hierarchical clustering (Euclidian distance, complete
linkage) at least one change greater than fourfold per row. (D) Only genes
changed greater than fourfold upon TNF-α stimulation were clustered
(method the same as C). NI: noninduced, I: TNF-α–induced (12 h, 10 ng∕mL).
Treatment with 1 (72 h) or 2 (1.5 h) both at 10 μM final concentration.













TNF-α, 369 genes (56.8%) were not repressed by either 1 or 2.
The polyamide 1 repressed a total of 428 genes (63.8%) that were
not induced by TNF-α or repressed by 2. Finally, the kinase
inhibitor 2 repressed a group of 105 genes (31.6%) that were
neither induced by TNF-α nor repressed by 1. Similar trends
albeit with a smaller overall number of genes were seen for the
intersection between TNF-α (up) 1 (down) and 2 (down). It has
to be kept in mind that the TNF-α stimulation can lead to the
activation of other regulatory circuits. The nonoverlapping sets
between TNF-α, 1, and 2 may stem from that to a degree.
Prior to conducting gene clustering analysis, more stringent
filtering criteria were applied to the gene pool discussed above.
Genes were kept where at least one fourfold change was obser-
vable upon TNF-α stimulation or treatment with either 1 or 2.
This procedure yielded a subset of 563 genes (Fig. 4C). A sub-
group of those was furthermore projected out by applying the
criterion of at least a fourfold change upon TNF-α treatment,
yielding 314 genes overall (Fig. 4D). From the gene panel pre-
sented in Fig. 4D, 15 representative genes were selected that
are known NF-κB targets (Fig. 5 A–C). Fig. 5A comprises five
genes for which the effect of the polyamide 1 and the authentic
inhibitor 2 are comparable, whereas in Fig. 5 B and C genes are
displayed that are affected by 1 but not 2 and vice versa.
We confirmed the validity of the RNA-seq approach for quan-
titative transcriptome analysis by conducting qRT-PCR experi-
ments on three representative genes from the panel displayed
in Fig. 5 (ICAM1, IL8, and SERPINE1). High correlation was
observed between the values obtained by the two techniques
(Table 2). The corresponding bar graphs for the qRT-PCR control
experiment are shown in Fig. S6.
Discussion
A large number of NF-κB inhibitors has been developed (6).
They can be broadly classified as upstream or downstream inhi-
bitors of NF-κB activity. The upstream inhibitors encompass
molecules which affect various aspects of response initiation, the
activity of the kinase complex IKK and the proteasome-mediated
degradation of the NF-κB inhibitor proteins IκB. The down-
stream inhibitors comprise compounds with the ability to modu-
late NF-κB nuclear functions—i.e., its nuclear translocation,
DNA binding, and transactivation. The main mode of action of
the polyamide 1 is likely rooted in its DNA-binding properties
and the resultant ability to displace transcription factors, which
would place it downstream of NF-κB activation and potentially
allow for a controlled regulation of a subgroup of the NF-κB
regulatome.
Given the feedback regulation mechanism of NF-κB, response
duration and magnitude can be affected. In order to shed light
onto that aspect, the expression levels of the principal constitu-
ents of the NF-κB regulatory circuit (p50, p65, IκBα, β, and ε, and
IKKα, β, and γ) were examined. Expression changes were sub-
stantially below twofold in most cases for both 1 and 2.
The consensus binding sequence of NF-κB has been identified
as 5′-GGGRNYYYCC-3′.(24) Our ChIP-seq experiments, con-
ducted with an antibody against the p65 subunit, determined
the binding motif to be 5′-NGGNNTTTCCN-3′. The first five
base pairs represent a consensus superset of the p50 half-site
(5′-NGGNN-3′ vs 5′-GGGRN-3′ in the consensus). The remain-
ing portion of the NF-κB binding motif, the p65 half-site, was
found to be substantially better defined (5′-TTTCC-3′ vs 5′-
YYYCC-3′ in the consensus motif). The polyamide 1 can hence
bind either the p50 half-site with one overhang into the p65
half-site (5′-NGGNNT-3′) or the reverse-complement of the
p65 half-site with one additional base pair downstream (5′-
NGGAAA-3′). Because of the overlap between the two potential
binding sites, simultaneous binding of two polyamide molecules
appears unlikely and the precise nature of the targeted binding
sequence will determine which of the two half-sites is bound.
Furthermore, in cellular context the affinities of the DNA for
the polyamide 1 can be substantially altered because of the
presence of higher order chromatin structures and further tran-
scription factors bound to the DNA. The melting temperature
analyses (Table 1) suggest that both the p50 and the p65 half-site
within the two κB sites are fully capable of binding 1. Given the
difference in sequence between the oligonucleotides employed,
quantitative comparisons between the ΔTm values should be
avoided.
The Py-Im polyamide 1 had comparable effects on IL6 and IL8
gene expression following the stimulation with both TNF-α and
IL1. This finding can be interpreted as an indication that 1 is act-
ing downstream of NF-κB activation and does not interfere with
the cytosolic signaling cascades that lead to its activation. Given
that the ChIP experiments demonstrated reduced p65 occupancy
at both the IL6 and IL8 proximal promoter and the Western blot
experiments showed that the polyamide does not impede nuclear
trafficking of p65, the combined data are suggestive of a DNA-
based mechanism of action for the Py-Im polyamide 1.
The implication of the genome-wide transcriptome analysis
(Fig. 4) is that the polyamide 1 possesses an acting profile that,
although bearing a certain resemblance with the authentic NF-κB
inhibitor 2, also possesses its own distinct features. As such,
Fig. 5. (A) Known NF-κB targets that are induced by TNF-α and repressed
by both 1 and 2. (B) The noninduced state is partially restored by 1 but
not 2. (C) The noninduced state is partially restored by 2 but not 1. NI: non-
induced, I: TNF-α–induced (12 h, 10 ng∕mL). Treatment with 1 (72 h) or 2
(1.5 h) both at 10 μM final concentration.
Table 2. Comparison of expression levels of ICAM1, IL8, and











ICAM1 2.9 5.2 3.8 5.7
IL8 2.3 8.4 2.7 7.0
SERPINE1 12.7 1.0 16.2 (1.1)
Treatment with 1 (72 h) or 2 (1.5 h) both at 10 μM final concentration. TNF-α
induction (12 h, 10 ng∕mL). Up-regulated genes have been put in brackets.
Table 3. Gene expression fold change upon polyamide treatment











CCL2 11.8 9.8 SERPINE1 12.7 CCL5 13.6
ICAM1 2.9 5.2 CSF1 4.4 EBI3 5.0
IL8 2.3 8.4 PLAU 5.7 PTGS2 2.6
SERPINA3 4.1 4.2 TRAF1 2.1 IRF1 2.4
TNFAIP3 2.3 3.4 NR3C1 (3.3) NFKBIA 2.0
A: Genes affected by 1 and 2; B: genes affected by 1 but not 2; C: genes
affected by 2 but not 1.
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neither 1 nor 2 do repress the entire TNF-α inductome. From the
total of 650 up-regulated genes, 67 (10.3%) are repressed by both
1 and 2, 115 (17.7%) by 1 but not 2, and 99 (15.2%) by 2 but not 1
at chosen cutoffs. From the set of 650 that were TNF-α–inducible,
369 genes (56.8%) were not affected by either 1 or 2. The fold
changes for the selected genes (Fig. 5) that are induced by TNF-α
and affected by 1 are listed in Table 3. Within the subset A, where
both 1 and 2 affected gene expression, the most pronounced dif-
ference in potency was noted for IL8 (2.3-fold with the polyamide
and 8.4-fold with PS1145). The other four genes experienced
comparable down-regulation effects between the polyamide
and the kinase inhibitor. Among these is TNFAIP3, which plays
an essential role in the negative regulation of NF-κB activation
(25, 26). Its repression could therefore extend the duration of the
NF-κB–mediated signaling cascade.
As for the gene subset B, where 1 but not 2 exhibited substan-
tial gene regulation effects, the most pronounced gene repression
was observed with SERPINE1 (12.7-fold down-regulation upon
treatment with 1). SERPINE1 (PAI-1) is the principal inhibitor
of the tissue-type plasminogen activator and the urokinase-type
plasminogen activator (PLAU) and hence an important drug tar-
get (27). It plays a pivotal role in inhibiting fibrinolysis and has
been implicated in diseases of high impact on the modern society,
such as myocardial infarction and atherosclerosis (28, 29). There
is evidence for SERPINE1 expression being regulated by NF-κB,
although the exact mechanism of action remains elusive (30). We
observe the gene being induced threefold by TNF-α. However,
the polyamide treatment results in a thirteenfold repression of
the gene, bringing it 4.5-fold below the basal expression level
in A549 cells. This observation could either imply constitutive
NF-κB–driven expression of the gene or represent an additional
manifestation of polyamide off-target effects. The ChIP-seq da-
taset allowed detecting three NF-κB binding events in the vicinity
of the SERPINE1 transcription start site, on the basis of the es-
tablished binding motif.* Interestingly, one of the principal pro-
tein targets of SERPINE1—PLAU—was found to be repressed
5.7-fold by the polyamide at the transcript level. In the gene sub-
set C (Table 3) the kinase inhibitor PS1145 (2) had the most pro-
nounced effect on the gene CCL5, although 1 did not affect its
expression.
Conclusion
We have developed the synthetic polyamide 1 capable of binding
the DNA sequences 5′WGGWWW-3′ and 5′GGGWWW-3′. Its
activity in cell culture has been assessed by qRT-PCR and RNA-
seq, which showed that the molecule affected some 30% of the
TNF-α–inducible transcriptome. ChIP experiments conducted on
the IL6 and IL8 promoters demonstrate that the molecule is cap-
able of reducing the NF-κB promoter occupancy for those genes.
The RNA-seq–based comparison between 1 and the established
NF-κB inhibitor PS1145 revealed that the two molecules affected
a common group of genes but additionally possessed nonoverlap-
ping effects, affecting comparable numbers of genes. From the
set of genes affected uniquely by 1, the strong repression of the
SERPINE1 gene is of potential interest because of the gene’s
role in myocardial infarction and atherosclerosis. The transcrip-
tion factor-targeted approach offers an alternative to the existing
NF-κB inhibitors and could possess interesting properties for the
treatment of inflammatory disorders. Animal model experiments
to study the effects of 1 in vivo are under way.
Materials and Methods
Polyamide Synthesis and Characterization. The polyamides 1 and 10 were
synthesized by following established solid phase synthesis protocols (31, 32).
Binding properties with respect to various DNA sequences were determined
by means of DNA thermal denaturation analyses. Cellular uptake was
assessed in live A549 cells by using the fluorescein conjugates 3 and 11 in
conjunction with confocal microscopy measurements (33). Water-soluble tet-
razolium-1 cell proliferation and viability assays were furthermore
conducted at different concentrations of 1. Detailed procedures can be found
in SI Text.
Gene Expression Analysis by quantitative RT-PCR. Total growth medium was
obtained by supplementing F12-K (Gibco) with 10% FBS and 1% penicil-
lin/streptomycin. A549 cells were plated in 12-well plates at a density of
2 × 104 mL−1. The cells were allowed to adhere (16–24 h) and the polyamide
1 subsequently dosed as a DMSO solution at specified concentrations, typi-
cally not exceeding 0.2% DMSO final concentration (vol∕vol). Untreated re-
ference samples were mock-treated with DMSO at equal volumes. The cells
were incubated with 1 for 48 or 72 h or where appropriate with PS1145 for
1.5–2 h and subsequently induced with human recombinant TNF-α (R&D, CF)
at 10 ng∕mL for 2 or 12 h. The mRNA was extracted by using the QIAGEN®
RNeasy mini kit following the standard purification protocol. The mRNA was
reverse-transcribed by using the Transcriptor First Strand cDNA Synthesis Kit
(Roche). Quantitative PCR was performed by using the FastStart Universal
SYBR GreenMaster (Rox) (Roche) on an ABI 7300 Real Time PCR System. Gene
expression was normalized against PPIA and in some cases additionally GUSB
as housekeeping genes. All primers yielded single amplicons as determined
by both melting denaturation analysis and agarose gel electrophoresis. The
following primer pairs were used. IL6: fwd. 5′-AGT GAG GAA CAA GCC AGA
GC rev. 5′-GTC AGG GGT GGT TAT TGC AT-3′; IL8: fwd. 5′-TCC TGA TTT CTG
CAG CTC TGT-3′ rev. 5′-AAA TTT GGG GTG GAA AGG TT-3′; PPIA: fwd. 5′-CAC
CGT GTT CTT CGA CAT TG-3′ rev. 5′-TTC TGC TGT CTT TGG GAC CT-3′; GUSB:
fwd. 5′-CTC ATT TGG AAT TTT GCC GAT T-3′ rev. 5′-CCC AGT GAA GAT CCC CTT
TTT A-3′.
Chromatin Immunoprecipitation. A549 cells were plated at 3 × 104 mL−1 in
500 cm2 dishes using 100 mL of the cellular suspension per dish. Cells were
allowed to adhere to the surface over 16–24 h and subsequently treated with
1 at 10 μM final concentration for 60–70 h. Cell synchronization by FBS star-
vation (0.5% over 12 h) after polyamide treatment did not change the rela-
tive promoter occupancy between the untreated and the polyamide-treated
samples. The cells were induced with TNF-α over various time periods, as
specified. Cross-linked chromatin was obtained by following established
two-step cross-linking protocols (34). The following primer pairs were used.
IL6: fwd. 5′-CCT CAC CCT CCA ACA AAG AT-3′ rev. 5′-TTG AGA CTC ATG GGA
AAA TCC-3′ (proximal IL6 promoter; chr7:22,766,715-22,766,767; hg19); IL8:
fwd. 5′-CAT CAG TTG CAA ATC GTG GA-3′ rev. 5′-TGC ACC CTC ATC TTT TCA
TT-3′ (proximal IL8 promoter; chr4:74,606,178-74,606,231; hg19). Further
specifications of chromatin shearing and isolation procedures can be found
in SI Text.
ChIP-seq Sample Preparation and Data Processing. Immunoprecipitated DNA
samples were combined, typically yielding a total of 5–10 ng. ChIP-seq
libraries were prepared by using standard Illumina reagents and protocols.
Single read sequencing with the read length of 38 nt was performed on
the Illumina GAIIx sequencer by following the manufacturer’s instructions,
typically producing 25–30million postfiltered reads per library. The data were
processed by employing standard program packages and analytical techni-
ques. See SI Text for details on interreplicate reproducibility and NF-κB bind-
ing motif statistics (Table S2).
RNA-seq Sample Preparation and Data Processing. Cells were grown as de-
scribed above, incubated with 1 over 72 h, and subsequently induced with
TNF-α for 12 h. Total RNAwas isolated by using the TRIzol procedure, yielding
70–100 μg total RNA per condition. The mRNA was enriched for using a
double poly-A selection. RNA-seq libraries were prepared by using standard
Illumina reagents and protocols. Single read sequencing with the read length
of 38 nt was performed on the Illumina GAIIx sequencer by following the
manufacturer’s instructions, typically producing 25–30 million postfiltered
reads per library. The sequencing data were analyzed by using the packages
Tophat (mapping against hg19) and Cufflinks (35). All data were processed
with the gencode.v4 annotation. See SI Text for interreplicate reproducibility
(Fig. S7) and data processing thresholds.
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